Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial

Publisher： Karger

E-ISSN： 1423-0232|82|2|67-74

ISSN： 0030-2414

Source： Oncology, Vol.82, Iss.2, 2012-02, pp. : 67-74

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study

By  

Oncology, Vol. 85, Iss. 1, 2013-07 ,pp. : 44-52

Karger

Access to resources Recommend Favorite

Phase II Trial of Docetaxel Therapy in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 70, Iss. 2, 2006-05 ,pp. : 154-158

Karger

Access to resources Recommend Favorite

A Phase II Evaluation of Clofazimine plus Doxorubicin in Advanced, Unresectable Primary Hepatocellular Carcinoma

By  

Oncology, Vol. 57, Iss. 3, 1999-10 ,pp. : 232-235

Karger

Access to resources Recommend Favorite

A phase II trial of second‐line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma

By  

CANCER, Vol. 121, Iss. 10, 2015-05 ,pp. : 1620-1627

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetic and Clinical Phase II Trial of Imatinib in Patients with Impaired Liver Function and Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 69, Iss. 5, 2005-12 ,pp. : 363-371

Karger

Access to resources Recommend Favorite